Robert Dreicer

Viscuse, P., Devitt, M., & Dreicer, R. (2024). Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?. JOURNAL OF NUCLEAR MEDICINE, 65(5), 679-685. doi:10.2967/jnumed.123.267006

Rencsok, E. M., Slopen, N., Autio, K., Morgans, A., McSwain, L., Barata, P. H., . . . Mucci, L. A. (2023). Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US. QUALITY OF LIFE RESEARCH, 32(11), 3209-3221. doi:10.1007/s11136-023-03468-0

Lowrance, W., Dreicer, R., Jarrard, D. F., Scarpato, K. R., Kim, S. K., Kirkby, E., . . . Cookson, M. S. (2023). Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). JOURNAL OF UROLOGY, 209(6), 1082-1090. doi:10.1097/JU.0000000000003452

Li, J., Huang, T., Hua, J., Wang, Q., Su, Y., Chen, P., . . . He, J. (2023). CD46 targeted ²¹²Pb alpha particle radioimmunotherapy for prostate cancer treatment. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 42(1). doi:10.1186/s13046-023-02636-x

Sadeghi, S., Quinn, D., Dorff, T., Pal, S., Groshen, S., Tsao-Wei, D., . . . Gill, P. S. (2023). EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 41(3), 640-+. doi:10.1200/JCO.21.02923

Agarwal, N., McGregor, B., Maughan, B. L., Dorff, T. B., Kelly, W., Fang, B., . . . Pal, S. (2022). Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). LANCET ONCOLOGY, 23(7), 899-909. doi:10.1016/S1470-2045(22)00278-9

Morgans, A. K., Chen, Y. -H., Jarrard, D. F., Carducci, M., Liu, G., Eisenberger, M., . . . Sweeney, C. J. (2022). Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. PROSTATE, 82(12), 1176-1185. doi:10.1002/pros.24369

Pal, S. K., Frankel, P. H., Mortazavi, A., Milowsky, M., Vaishampayan, U., Parikh, M., . . . Lara, P. N. J. (2021). Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma A Phase 2 Randomized Clinical Trial. JAMA ONCOLOGY, 7(10), 1536-1543. doi:10.1001/jamaoncol.2021.3441

Pal, S. K., McGregor, B., Suarez, C., Tsao, C. -K., Kelly, W., Vaishampayan, U., . . . Agarwal, N. (2021). Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. JOURNAL OF CLINICAL ONCOLOGY, 39(33), 3725-+. doi:10.1200/JCO.21.00939

Rosenberg, J. E., Ballman, K. A., Halabi, S., Atherton, P. J., Mortazavi, A., Sweeney, C., . . . Morris, M. J. (2021). Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). JOURNAL OF CLINICAL ONCOLOGY, 39(22), 2486-+. doi:10.1200/JCO.21.00286

Smith, S. M., Wachter, K., Burris, H. A. I. I. I., Schilsky, R. L., George, D. J., Peterson, D. E., . . . Uzzo, R. (2021). Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. JOURNAL OF CLINICAL ONCOLOGY, 39(10), 1165-+. doi:10.1200/JCO.20.03420

Wang, S., Li, J., Hua, J., Su, Y., Beckford-Vera, D. R., Zhao, W., . . . He, J. (2021). Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. CLINICAL CANCER RESEARCH, 27(5), 1305-1315. doi:10.1158/1078-0432.CCR-20-3310

Bryce, A. H., Chen, Y. H., Liu, G., Carducci, M. A., Jarrard, D. M., Garcia, J. A., . . . Sweeney, C. J. (2020). Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. EUROPEAN UROLOGY ONCOLOGY, 3(6), 717-724. doi:10.1016/j.euo.2020.07.001

Bedke, J., Merseburger, A. S., Loriot, Y., Castellano, D., Choy, E., Duran, I., . . . Sternberg, C. N. (2021). Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. EUROPEAN UROLOGY FOCUS, 7(5), 1084-1091. doi:10.1016/j.euf.2020.10.009

Lowrance, W. T., Breau, R. H., Chou, R., Chapin, B. F., Crispino, T., Dreicer, R., . . . Cookson, M. S. (2021). Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. JOURNAL OF UROLOGY, 205(1), 22-29. doi:10.1097/JU.0000000000001376

Lowrance, W. T., Breau, R. H., Chou, R., Chapin, B. F., Crispino, T., Dreicer, R., . . . Cookson, M. S. (2021). Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. JOURNAL OF UROLOGY, 205(1), 14-21. doi:10.1097/JU.0000000000001375

Sonpavde, G., Manitz, J., Gao, C., Tayama, D., Kaiser, C., Hennessy, D., . . . Pond, G. R. (2020). Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. JOURNAL OF UROLOGY, 204(6), 1173-1179. doi:10.1097/JU.0000000000001199

Aragon-Ching, J. B., & Dreicer, R. (2020). Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. EXPERT REVIEW OF ANTICANCER THERAPY, 20(6), 483-490. doi:10.1080/14737140.2020.1770087

Dreicer, R. (2020). New mitomycin formulation for low-grade upper tract urothelial cancer Comment. LANCET ONCOLOGY, 21(6), 735-736. doi:10.1016/S1470-2045(20)30159-5

Hearn, J. W. D., Sweeney, C. J., Almassi, N., Reichard, C. A., Reddy, C. A., Li, H., . . . Sharifi, N. (2020). HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA ONCOLOGY, 6(4). doi:10.1001/jamaoncol.2019.6496

Antonarakis, E. S., Velho, P. I., Fu, W., Wang, H., Agarwal, N., Santos, V. S., . . . Hussain, M. (2020). CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO PRECISION ONCOLOGY, 4, 370-381. doi:10.1200/PO.19.00399

Halwani, A. S., Rasmussen, K. M., Patil, V., Li, C. C., Yong, C. M., Burningham, Z., . . . Sauer, B. C. (2020). Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 38(1). doi:10.1016/j.urolonc.2019.09.027

VanderWeele, D. J., Antonarakis, E. S., Carducci, M. A., Dreicer, R., Fizazi, K., Gillessen, S., . . . Hussain, M. (2019). Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. JOURNAL OF CLINICAL ONCOLOGY, 37(32), 2961-+. doi:10.1200/JCO.19.01595

Dreicer, R. (2019). Adoption of Abiraterone and Enzalutamide by Urologists. UROLOGY, 131, 182. doi:10.1016/j.urology.2019.05.016

Zahoor, H., Mir, M. C., Barata, P. C., Stephenson, A. J., Campbell, S. C., Fergany, A., . . . Garcia, J. A. (2019). Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer. INVESTIGATIONAL NEW DRUGS, 37(6), 1231-1238. doi:10.1007/s10637-018-00716-w

Barata, P. C., Magi-Galluzzi, C., Gupta, R., Dreicer, R., Klein, E. A., & Garcia, J. A. (2019). Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis. CLINICAL GENITOURINARY CANCER, 17(5), 366-372. doi:10.1016/j.clgc.2019.05.021

Koshkin, V. S., Mir, M. C., Barata, P., Gul, A., Gupta, R., Stephenson, A. J., . . . Garcia, J. A. (2019). Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. INVESTIGATIONAL NEW DRUGS, 37(3), 559-566. doi:10.1007/s10637-019-00778-4

Devitt, M. E., & Dreicer, R. (2019). Evolving Role of Genomics in Genitourinary Neoplasms.. Acta medica academica, 48(1), 68-77. doi:10.5644/ama2006-124.243

Pal, S. K., Miller, M. J., Agarwal, N., Chang, S. M., Chavez-MacGregor, M., Cohen, E., . . . Johnson, B. E. (2019). Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. JOURNAL OF CLINICAL ONCOLOGY, 37(10), 834-+. doi:10.1200/JCO.18.02037

Petrylak, D. P., Kantoff, P., Vogelzang, N. J., Mega, A., Fleming, M. T., Stephenson, J. J. J., . . . Israel, R. J. (2019). Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. PROSTATE, 79(6), 604-613. doi:10.1002/pros.23765

Scher, H. I., Mccormack, R. T., Molina, A., Smith, M. R., Dreicer, R., Saad, F., . . . Heller, G. (2019). transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY, 37(7). doi:10.1200/JCO.2019.37.7_suppl.143

Balar, A. V., Dreicer, R., Loriot, Y., Perez-Gracia, J. L., Hoffman-Censits, J. H., Petrylak, D. P., . . . Rosenberg, J. E. (2019). Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).. JOURNAL OF CLINICAL ONCOLOGY, 37(7). doi:10.1200/JCO.2019.37.7_suppl.394

Loriot, Y., Balar, A. V., Dreicer, R., Hoffman-Censits, J. H., Perez-Gracia, J. L., Petrylak, D. P., . . . Rosenberg, J. E. (2019). Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC).. JOURNAL OF CLINICAL ONCOLOGY, 37(15). doi:10.1200/JCO.2019.37.15_suppl.4527

Sonpavde, G., Manitz, J., Gao, C., Hennessy, D., Makari, D., Niegisch, G., . . . Pond, G. R. (2019). 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.. JOURNAL OF CLINICAL ONCOLOGY, 37(15). doi:10.1200/JCO.2019.37.15_suppl.4552

Hearn, J. W. D., Sweeney, C., Almassi, N., Reichard, C. A., Reddy, C. A., Hobbs, B., . . . Sharifi, N. (2019). HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.. JOURNAL OF CLINICAL ONCOLOGY, 37(15). doi:10.1200/JCO.2019.37.15_suppl.5020

Grivas, P., Puligandla, M., Cole, S., Courtney, K. D., Dreicer, R., Gartrell, B. A., . . . Carducci, M. A. (2019). PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC).. JOURNAL OF CLINICAL ONCOLOGY, 37(15). doi:10.1200/JCO.2019.37.15_suppl.TPS4594

Basch, E. M., Scholz, M., de Bono, J. S., Vogelzang, N., de Souza, P., Marx, G., . . . Scher, H. I. (2019). Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. EUROPEAN UROLOGY, 75(6), 929-937. doi:10.1016/j.eururo.2018.11.033

Perazella, M. A., Dreicer, R., & Rosner, M. H. (2018). Screening for renal cell carcinoma in dialysis patients Reply. KIDNEY INTERNATIONAL, 94(6), 1238-1239. doi:10.1016/j.kint.2018.08.023

Barata, P. C., Cooney, M., Mendiratta, P., Gupta, R., Dreicer, R., & Garcia, J. A. (2019). Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. INVESTIGATIONAL NEW DRUGS, 37(2), 331-337. doi:10.1007/s10637-018-0687-5

Autio, K. A., Dreicer, R., Anderson, J., Garcia, J. A., Alva, A., Hart, L. L., . . . Scher, H. I. (2018). Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer A Phase 2 Clinical Trial. JAMA ONCOLOGY, 4(10), 1344-1351. doi:10.1001/jamaoncol.2018.2168

Barata, P. C., Cooney, M., Mendiratta, P., Tyler, A., Dreicer, R., & Garcia, J. A. (2018). Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study. INVESTIGATIONAL NEW DRUGS, 36(6), 1085-1092. doi:10.1007/s10637-018-0660-3

Monk, P., Liu, G., Stadler, W. M., Geyer, S., Huang, Y., Wright, J., . . . Garcia, J. A. (2018). Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). INVESTIGATIONAL NEW DRUGS, 36(5), 919-926. doi:10.1007/s10637-018-0630-9

Heller, G., McCormack, R., Kheoh, T., Molina, A., Smith, M. R., Dreicer, R., . . . Scher, H. I. (2018). Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply. JOURNAL OF CLINICAL ONCOLOGY, 36(22), 2354-2355. doi:10.1200/JCO.2018.78.2672

Perazella, M. A., Dreicer, R., & Rosner, M. H. (2018). Renal cell carcinoma for the nephrologist. KIDNEY INTERNATIONAL, 94(3), 471-483. doi:10.1016/j.kint.2018.01.023

Barata, P., Cooney, M., Tyler, A., Wright, J., Dreicer, R., & Garcia, J. A. (2018). A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). INVESTIGATIONAL NEW DRUGS, 36(3), 451-457. doi:10.1007/s10637-018-0574-0

Gravis, G., Boher, J. -M., Chen, Y. -H., Liu, G., Fizazi, K., Carducci, M. A., . . . Sweeney, C. (2018). Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. EUROPEAN UROLOGY, 73(6), 847-855. doi:10.1016/j.eururo.2018.02.001

Kyriakopoulos, C. E., Chen, Y. -H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., . . . Sweeney, C. J. (2018). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. JOURNAL OF CLINICAL ONCOLOGY, 36(11), 1080-+. doi:10.1200/JCO.2017.75.3657

Heymach, J., Krilov, L., Alberg, A., Baxter, N., Chang, S. M., Corcoran, R., . . . Burstein, H. (2018). Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. JOURNAL OF CLINICAL ONCOLOGY, 36(10), 1020-+. doi:10.1200/JCO.2017.77.0446

Mittal, K., Derosa, L., Albiges, L., Wood, L., Elson, P., Gilligan, T., . . . Rini, B. (2018). Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. CLINICAL GENITOURINARY CANCER, 16(3), E663-E667. doi:10.1016/j.clgc.2017.12.014

Armstrong, A. J., Antonarakis, E. S., Taplin, M. -E., Kelly, W. K., Beltran, H., Fizazi, K., . . . Scher, H. I. (2018). Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. ANNALS OF ONCOLOGY, 29(1), 23-25. doi:10.1093/annonc/mdx648

Heller, G., McCormack, R., Kheoh, T., Molina, A., Smith, M. R., Dreicer, R., . . . Scher, H. I. (2018). Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. JOURNAL OF CLINICAL ONCOLOGY, 36(6), 572-+. doi:10.1200/JCO.2017.75.2998

Harshman, L. C., Chen, Y. -H., Liu, G., Carducci, M. A., Jarrard, D., Dreicer, R., . . . Sweeney, C. J. (2018). Seven- Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. JOURNAL OF CLINICAL ONCOLOGY, 36(4), 376-+. doi:10.1200/JCO.2017.75.3921

Stein, C. A., Levin, R., Given, R., Higano, C. S., Nemeth, P., Bosch, B., . . . Dreicer, R. (2018). Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 36(2). doi:10.1016/j.urolonc.2017.10.018

Dreicer, R. (2017). New option for cisplatin-ineligible urothelial cancer. LANCET ONCOLOGY, 18(11), 1428-1430. doi:10.1016/S1470-2045(17)30602-2

Chang, S. S., Bochner, B. H., Chou, R., Dreicer, R., Kamat, A. M., Lerner, S. P., . . . Holzbeierlein, J. M. (2017). Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. JOURNAL OF ONCOLOGY PRACTICE, 13(9), 621-+. doi:10.1200/JOP.2017.024919

Chang, S. S., Bochner, B. H., Chou, R., Dreicer, R., Kamat, A. M., Lerner, S. P., . . . Holzbeierlein, J. M. (2017). Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. JOURNAL OF UROLOGY, 198(3), 552-559. doi:10.1016/j.juro.2017.04.086

Dreicer, R. (2017). Chemotherapy for advanced urothelial cancer: end of the beginning?. LANCET ONCOLOGY, 18(5), 567-569. doi:10.1016/S1470-2045(17)30241-3

Dreicer, R. (2017). Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. UROLOGY, 102, 157-158. doi:10.1016/j.urology.2016.10.065

Halwani, A., Burningham, Z., Rasmussen, K. M., Patil, V., Narayanan, S., Lin, S. -W., . . . Sauer, B. C. (2017). Practice patterns in metastatic castration-resistant prostate cancer (mCRPC): Evidence from the veterans health administration. ANNALS OF ONCOLOGY, 28. Retrieved from https://www.webofscience.com/

Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., . . . Bajorin, D. F. (2017). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. LANCET, 389(10064), 67-76. doi:10.1016/S0140-6736(16)32455-2

Milowsky, M. I., Galsky, M. D., Morris, M. J., Crona, D. J., George, D. J., Dreicer, R., . . . Scher, H. I. (2016). Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 34(12). doi:10.1016/j.urolonc.2016.07.005

Dreicer, R. (2016). Immunomodulatory treatment in urothelial cancer. LANCET ONCOLOGY, 17(11), 1475-1477. doi:10.1016/S1470-2045(16)30497-1

Dreicer, R. (2016). Highlights in Genitourinary (Prostate) Cancer. JAMA ONCOLOGY, 2(10), 1257-1258. doi:10.1001/jamaoncol.2016.3325

Chittoria, N., Haddad, H., Elson, P., Tannir, N. M., Wood, L. S., Dreicer, R., . . . Jonasch, E. (2016). Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC CANCER, 16. doi:10.1186/s12885-016-2282-5

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., . . . Dreicer, R. (2016). Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. LANCET, 387(10031), 1909-1920. doi:10.1016/S0140-6736(16)00561-4

Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., . . . Armstrong, A. J. (2016). Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. JOURNAL OF CLINICAL ONCOLOGY, 34(12), 1402-+. doi:10.1200/JCO.2015.64.2702

Dreicer, R. (2016). Sequence and Cross-Resistance: Challenges for Optimal Use of Next-Generation Anti-Androgen Therapies. AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 12(8), 4-6. Retrieved from https://www.webofscience.com/

Sohal, D. P. S., Rini, B. I., Khorana, A. A., Dreicer, R., Abraham, J., Procop, G. W., . . . Bolwell, B. J. (2016). Prospective Clinical Study of Precision Oncology in Solid Tumors. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 108(3). doi:10.1093/jnci/djv332

Mitin, T., George, A., Zietman, A. L., Heney, N. M., Kaufman, D. S., Uzzo, R. G., . . . Shipley, W. U. (2016). Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 94(1), 67-74. doi:10.1016/j.ijrobp.2015.09.030

Sweeney, C. J., Chen, Y. -H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., . . . DiPaola, R. S. (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 373(8), 737-746. doi:10.1056/NEJMoa1503747

Fizazi, K., & Dreicer, R. (2015). The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel? Reply. JOURNAL OF CLINICAL ONCOLOGY, 33(28), 3222-U208. doi:10.1200/JCO.2015.62.4684

Pantuck, A. J., Pettaway, C. A., Dreicer, R., Corman, J., Katz, A., Ho, A., . . . Heber, D. (2015). A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES, 18(3), 242-248. doi:10.1038/pcan.2015.32

Li, Z., Bishop, A. C., Alyamani, M., Garcia, J. A., Dreicer, R., Bunch, D., . . . Sharifi, N. (2015). Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. NATURE, 523(7560), 347-+. doi:10.1038/nature14406

Dreicer, R. (2015). Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.. Clinical advances in hematology & oncology : H&O, 13(5), 293-295.

Rini, B. I., Plimack, E. R., Takagi, T., Elson, P., Wood, L. S., Dreicer, R., . . . Campbell, S. C. (2015). A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. JOURNAL OF UROLOGY, 194(2), 297-303. doi:10.1016/j.juro.2015.03.096

Saad, F., Fizazi, K., Jinga, V., Efstathiou, E., Fong, P. C., Hart, L. L., . . . de Wit, R. (2015). Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. LANCET ONCOLOGY, 16(3), 338-348. doi:10.1016/S1470-2045(15)70027-6

Zhao, B., Yerram, N. K., Gao, T., Dreicer, R., & Klein, E. A. (2015). Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 33(4). doi:10.1016/j.urolonc.2015.01.001

Fizazi, K., Jones, R., Oudard, S., Efstathiou, E., Saad, F., de Wit, R., . . . Dreicer, R. (2015). Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. JOURNAL OF CLINICAL ONCOLOGY, 33(7), 723-731. doi:10.1200/JCO.2014.56.5119

Li, Z., Bishop, A. C., Alyamani, M., Garcia, J. A., Dreicer, R., & Bunch, D. (2015). METABOLIC CONVERSION OF ABIRATERONE CONTRIBUTES TO ITS ANTITUMOR EFFECTS. CANCER DISCOVERY, 5(8), 791. doi:10.1158/2159-8290.CD-RW2015-111

Drake, C. G., Quinn, D., Dreicer, R., Antonarakis, E., Shore, N., Corman, J., . . . Petrylak, D. (2015). Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). Journal for ImmunoTherapy of Cancer, 3(Suppl 2), P145. doi:10.1186/2051-1426-3-s2-p145

Dreicer, R., Li, J., & Armstrong, A. J. (2015). Docetaxel Still the Optimal First Choice for Symptomatic Metastatic Castration-Resistant Prostate Cancer. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 13(5), 293-+. Retrieved from https://www.webofscience.com/

Dreicer, R., Li, J., & Andrew, J. (2015). Radium-223 Is the Preferred Therapy in Bone-Predominant Symptomatic Metastatic Castration-Resistant Prostate Cancer. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 13(5), 293-+. Retrieved from https://www.webofscience.com/

Dreicer, R. (2014). Managing advanced prostate cancer: the rapidly changing treatment landscape.. The American journal of managed care, 20(12 Suppl), S282-S289.

Dreicer, R. (2015). Interdisciplinary Management of Locally Advanced and Metastatic Genitourinary Cancers: A Team Sport. JOURNAL OF UROLOGY, 193(2), 389-390. doi:10.1016/j.juro.2014.11.076

Dinney, C. P. N., Hansel, D., McConkey, D., Shipley, W., Hagan, M., Dreicer, R., . . . Bajorin, D. (2014). Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 32(8), 1108-1115. doi:10.1016/j.urolonc.2013.10.021

Sonpavde, G., Pond, G. R., Rosenberg, J. E., Bajorin, D. F., Regazzi, A. M., Choueiri, T. K., . . . Bellmunt, J. (2015). Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma sdfhzdfh. CLINICAL GENITOURINARY CANCER, 13(2), 185-192. doi:10.1016/j.clgc.2014.09.004

McNeel, D. G., Gardner, T. A., Higano, C. S., Kantoff, P. W., Small, E. J., Wener, M. H., . . . Dreicer, R. (2014). A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T. CANCER IMMUNOLOGY RESEARCH, 2(10), 988-999. doi:10.1158/2326-6066.CIR-14-0073

Dreicer, R. (2014). How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer. CANADIAN JOURNAL OF UROLOGY, 21, 93-97. Retrieved from https://www.webofscience.com/

Mukherjee, S., Reddy, C. A., Ciezki, J. P., Abdel-Wahab, M., Tiu, R. V., Copelan, E., . . . Sekeres, M. A. (2014). Risk for Developing Myelodysplastic Syndromes in Prostate Cancer Patients Definitively Treated With Radiation. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(3). doi:10.1093/jnci/djt462

Najjar, Y. G., Mittal, K., Elson, P., Wood, L., Garcia, J. A., Dreicer, R., & Rini, B. I. (2014). A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. EUROPEAN JOURNAL OF CANCER, 50(6), 1084-1089. doi:10.1016/j.ejca.2014.01.025

Dreicer, R., MacLean, D., Suri, A., Stadler, W. M., Shevrin, D., Hart, L., . . . Agus, D. B. (2014). Phase I/II Trial of Orteronel (TAK-700)-an Investigational 17,20-Lyase Inhibitor-in Patients with Metastatic Castration-Resistant Prostate Cancer. CLINICAL CANCER RESEARCH, 20(5), 1335-1344. doi:10.1158/1078-0432.CCR-13-2436

Fireman, K., Dreicer, R., Schuermeyer, I., Poole, C., & Savage, B. (2014). Setting Limits With Cancer Patients: A Challenge for Oncology Staff. PSYCHO-ONCOLOGY, 23, 67-68. Retrieved from https://www.webofscience.com/

Dreicer, R. (2014). EDITORIAL COMMENT. UROLOGY, 83(2), 264-265. doi:10.1016/j.urology.2013.10.031

Grivas, P. D., Daignault, S., Tagawa, S. T., Nanus, D. M., Stadler, W. M., Dreicer, R., . . . Hussain, M. (2014). Double-Blind, Randomized, Phase 2 Trial of Maintenance Sunitinib Versus Placebo After Response to Chemotherapy in Patients With Advanced Urothelial Carcinoma. CANCER, 120(5), 692-701. doi:10.1002/cncr.28477

Salem, M. E., Shah, S. N., Elson, P., Garcia, J. A., Wood, L. S., Medsinge, A., . . . Rini, B. I. (2014). Computed Tomography Characteristics of Unresectable Primary Renal Cell Carcinoma Treated With Neoadjuvant Sunitinib. CLINICAL GENITOURINARY CANCER, 12(2), 117-123. doi:10.1016/j.clgc.2013.08.001

Garcia, J. A., Elson, P., Tyler, A., Triozzi, P., & Dreicer, R. (2014). Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): Results from a phase I-II clinical trial. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 32(1). doi:10.1016/j.urolonc.2012.12.004

Galsky, M. D., Hendricks, R., Svatek, R., Bangs, R., Hoffman-Censits, J., Clement, J., . . . Rosenberg, J. (2013). Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer. CANCER, 119(11), 1994-1998. doi:10.1002/cncr.27973

Dreicer, R. (2013). "Missing the target" in urothelial cancer.. Oncology (Williston Park, N.Y.), 27(3), 227-233.

Dreicer, R., Garcia, J., Rini, B., Vogelzang, N., Srinivas, S., Somer, B., . . . Raghavan, D. (2013). A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. INVESTIGATIONAL NEW DRUGS, 31(4), 1044-1050. doi:10.1007/s10637-013-9940-0

Zhou, N., Singh, K., Mir, M. C., Parker, Y., Lindner, D., Dreicer, R., . . . Hansel, D. E. (2013). The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo. CLINICAL CANCER RESEARCH, 19(7), 1717-1728. doi:10.1158/1078-0432.CCR-12-2383

Dreicer, R. (2013). "Missing the Target" in Urothelial Cancer THE VERDOORN/KESSLER/FLAIG ARTICLE REVIEWED. ONCOLOGY-NEW YORK, 27(3), 227-233. Retrieved from https://www.webofscience.com/

Triozzi, P. L., Achberger, S., Aldrich, W., Elson, P., Garcia, J., & Dreicer, R. (2012). Differential Immunologic and MicroRNA Effects of 2 Dosing Regimens of Recombinant Human Granulocyte/Macrophage Colony Stimulating Factor. JOURNAL OF IMMUNOTHERAPY, 35(7), 587-594. doi:10.1097/CJI.0b013e31826b20b6

Sternberg, C. N., Bellmunt, J., Sonpavde, G., Siefker-Radtke, A. O., Stadler, W. M., Bajorin, D. F., . . . Quinn, D. I. (2013). ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma-Neoadjuvant and Adjuvant Settings. EUROPEAN UROLOGY, 63(1), 58-66. doi:10.1016/j.eururo.2012.08.010

Cooney, M. M., Nock, C., Bokar, J., Krishnamurthi, S., Gibbons, J., Rodal, M. B., . . . Dowlati, A. (2012). Phase I trial of pomalidomide given for patients with advanced solid tumors. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 70(5), 755-761. doi:10.1007/s00280-012-1919-6

Dreicer, R. (2012). Systemic therapy for advanced adrenal cancer. JOURNAL OF SURGICAL ONCOLOGY, 106(5), 643-646. doi:10.1002/jso.23078

Rini, B. I., Garcia, J., Elson, P., Wood, L., Shah, S., Stephenson, A., . . . Campbell, S. (2012). The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery. JOURNAL OF UROLOGY, 187(5), 1548-1554. doi:10.1016/j.juro.2011.12.075

Ali, K. B., Shah, S. N., Wood, L. S., Garcia, J. A., Dreicer, R., Gilligan, T. D., & Rini, B. I. (2012). Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib.. J Clin Oncol, 30(5_suppl), 420. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27968093

Sadeghi, S., Albiqes, L., Wood, L. S., Black, S. L., Gilligan, T. D., Dreicer, R., . . . Rini, B. I. (2012). Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma Feasibility and Clinical Outcome (vol 118, pg 3277, 2012). CANCER, 118(21), 5448. doi:10.1002/cncr.27534

Garcia, J. A., Elson, P., Cooney, M. M., Tyler, A. J., & Dreicer, R. (2012). Targeting mTOR and VEGF in CRPC: Preliminary results of a phase I/II trial of temsirolimus (T) and bevacizumab (B) in docetaxel-refractory metastatic CRPC.. JOURNAL OF CLINICAL ONCOLOGY, 30(15). Retrieved from https://www.webofscience.com/

Dreicer, R. (2012). Sequencing of therapies in advanced prostate cancer.. Oncology (Williston Park, N.Y.), 26(1), 82-84.

Dreicer, R. (2012). The Future of Drug Development in Urothelial Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(5), 473-475. doi:10.1200/JCO.2011.39.5566

Sadeghi, S., Albiges, L., Wood, L. S., Black, S. L., Gilligan, T. D., Dreicer, R., . . . Rini, B. I. (2012). Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma Feasibility and Clinical Outcome. CANCER, 118(13), 3277-3282. doi:10.1002/cncr.26666

Moul, J. W., & Dreicer, R. (2011). Focusing on Testosterone. UROLOGY, 78(5), S476-S477. doi:10.1016/j.urology.2011.06.004

Moul, J. W., & Dreicer, R. (2011). New Data, New Paradigms for Treating Patients With Prostate Cancer: Introduction. UROLOGY, 78(5), S475. doi:10.1016/j.urology.2011.03.061

Moul, J. W., Kibel, A. S., Roach, M. I. I. I., & Dreicer, R. (2011). Indications and Practice With Androgen Deprivation Therapy. UROLOGY, 78(5), S478-S481. doi:10.1016/j.urology.2011.04.025

Moul, J. W., Evans, C. P., Gomella, L. G., Roach, M. I. I. I., & Dreicer, R. (2011). Traditional Approaches to Androgen Deprivation Therapy. UROLOGY, 78(5), S485-S493. doi:10.1016/j.urology.2011.05.051

Dreicer, R., Gleave, M., Kibel, A. S., Thrasher, J. B., & Moul, J. W. (2011). Targeting the Androgen Receptor-Theory and Practice. UROLOGY, 78(5), S482-S484. doi:10.1016/j.urology.2011.05.052

Dreicer, R., & Moul, J. W. (2011). Conclusion. UROLOGY, 78(5), S499. doi:10.1016/j.urology.2011.03.060

Dreicer, R., Bajorin, D. F., McLeod, D. G., Petrylak, D. P., & Moul, J. W. (2011). New Data, New Paradigms for Treating Prostate Cancer Patients-VI: Novel Hormonal Therapy Approaches. UROLOGY, 78(5), S494-S498. doi:10.1016/j.urology.2011.06.058

Rosen, L. S., Senzer, N., Mekhail, T., Ganapathi, R., Chai, F., Savage, R. E., . . . Dreicer, R. (2011). A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors. CLINICAL CANCER RESEARCH, 17(24), 7754-7764. doi:10.1158/1078-0432.CCR-11-1002

Kim, J. J., Vaziri, S. A. J., Rini, B. I., Elson, P., Garcia, J. A., Wirka, R., . . . Ganapathi, R. (2012). Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. CANCER, 118(7), 1946-1954. doi:10.1002/cncr.26491

Galsky, M. D., Chen, G. J., Oh, W. K., Bellmunt, J., Roth, B. J., Petrioli, R., . . . Sonpavde, G. (2011). Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.. J Clin Oncol, 29(15_suppl), e15027. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28020585

Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W. K., . . . Bellmunt, J. (2011). Treatment of Patients With Metastatic Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy. JOURNAL OF CLINICAL ONCOLOGY, 29(17), 2432-2438. doi:10.1200/JCO.2011.34.8433

Galsky, M. D., Chen, G. J., Oh, W. K., Bellmunt, J., Roth, B. J., Petrioli, R., . . . Sonpavde, G. (2012). Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. ANNALS OF ONCOLOGY, 23(2), 406-410. doi:10.1093/annonc/mdr156

Ching, C. B., Amin, M. B., Tubbs, R. R., Elson, P., Platt, E., Dreicer, R., . . . Hansel, D. E. (2011). HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. MODERN PATHOLOGY, 24(8), 1111-1119. doi:10.1038/modpathol.2011.69

Schwandt, A., Garcia, J. A., Elson, P., Wyckhouse, J., Finke, J. H., Ireland, J., . . . Rini, B. I. (2011). Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining. JOURNAL OF CLINICAL IMMUNOLOGY, 31(4), 690-698. doi:10.1007/s10875-011-9530-x

Fitzpatrick, J. M., Bellmunt, J., Dreicer, R., Fleshner, N. E., Logothetis, C. J., Moul, J. W., . . . Zlotta, A. (2011). Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU INTERNATIONAL, 107, 1-12. doi:10.1111/j.1464-410X.2010.10035.x

Sadeghi, S., Albiges, L., Wood, L. S., Black, S. L., Gilligan, T. D., Dreicer, R., . . . Rini, B. I. (2011). Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma (mRCC): Feasibility and clinical outcome.. J Clin Oncol, 29(7_suppl), 307. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27968324

Sonpavde, G., Galsky, M. D., Chen, G. J., Bellmunt, J., Roth, B. J., Petrioli, R., . . . Oh, W. K. (2011). Meta-analysis of randomized trials comparing cisplatin versus carboplatin-based regimens for the first-line therapy of metastatic transitional cell carcinoma of the urothelium (TCCU).. J Clin Oncol, 29(7_suppl), 247. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27968530

Galsky, M. D., Hahn, N. M., Rosenberg, J. E., Sonpavde, G., Oh, W. K., Dreicer, R., . . . Cisplatin Ineligibility in Bladder Cancer Working Group. (2011). Defining "cisplatin ineligible" patients with metastatic bladder cancer.. J Clin Oncol, 29(7_suppl), 238. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27968673

Garcia, J. A., Stephenson, A. J., Ireland, J., Finke, J., Elson, P., Schaaf, L., . . . Dreicer, R. (2011). Sunitinib in BCG-refractory non-muscle-invasive transitional cell carcinoma of the bladder.. J Clin Oncol, 29(7_suppl), 262. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/27968589

Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W. K., . . . Bellmunt, J. (2011). A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. LANCET ONCOLOGY, 12(3), 211-214. doi:10.1016/S1470-2045(10)70275-8

Garcia, J. A., & Dreicer, R. (2011). Immunotherapy in Castration-Resistant Prostate Cancer: Integrating Sipuleucel-T Into Our Current Treatment Paradigm. ONCOLOGY-NEW YORK, 25(3), 242-249. Retrieved from https://www.webofscience.com/

Garcia, J. A., Mekhail, T., Elson, P., Wood, L., Bukowski, R. M., Dreicer, R., & Rini, B. I. (2012). Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma. BJU INTERNATIONAL, 109(1), 63-69. doi:10.1111/j.1464-410X.2010.10011.x

Sonpavde, G., Galsky, M. D., Chen, G. J., Bellmunt, J., Roth, B. J., Petrioli, R., . . . Oh, W. K. (2011). Meta-analysis of randomized trials comparing cisplatin versus carboplatin-based regimens for the first-line therapy of metastatic transitional cell carcinoma of the urothelium (TCCU). JOURNAL OF CLINICAL ONCOLOGY, 29(7). doi:10.1200/jco.2011.29.7_suppl.247

Karam, J. A., Rini, B. I., Varella, L., Garcia, J. A., Dreicer, R., Choueiri, T. K., . . . Tannir, N. M. (2011). Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. JOURNAL OF UROLOGY, 185(2), 439-444. doi:10.1016/j.juro.2010.09.086

Basappa, N. S., Elson, P., Golshayan, A. -R., Wood, L., Garcia, J. A., Dreicer, R., & Rini, B. I. (2011). The Impact of Tumor Burden Characteristics in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. CANCER, 117(6), 1183-1189. doi:10.1002/cncr.25713

Garcia, J. A., Hutson, T. E., Shepard, D., Elson, P., & Dreicer, R. (2011). Gemcitabine and Docetaxel in Metastatic, Castrate-Resistant Prostate Cancer Results From a Phase 2 Trial. CANCER, 117(4), 752-757. doi:10.1002/cncr.25457

Garcia, J. A., Mekhail, T., Elson, P., Triozzi, P., Nemec, C., Dreicer, R., . . . Rini, B. I. (2011). Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU INTERNATIONAL, 107(4), 562-570. doi:10.1111/j.1464-410X.2010.09573.x

Dreicer, R. (2010). Androgen deprivation therapy in patients with advanced prostate cancer.. The journal of supportive oncology, 8(5), 209-211. doi:10.1016/j.suponc.2010.09.001

Garcia, J. A., Hutson, T. E., Elson, P., Cowey, C. L., Gilligan, T., Nemec, C., . . . Rini, B. I. (2010). Sorafenib in Patients With Metastatic Renal Cell Carcinoma Refractory to Either Sunitinib or Bevacizumab. CANCER, 116(23), 5383-5390. doi:10.1002/cncr.25327

Shepard, D. R., Cooney, M. M., Elson, P., Bukowski, R. M., Dreicer, R., Rini, B. I., & Garcia, J. A. (2012). A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. INVESTIGATIONAL NEW DRUGS, 30(1), 364-367. doi:10.1007/s10637-010-9516-1

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., . . . Young, J. (2010). Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.. NEW ENGLAND JOURNAL OF MEDICINE, 363(5), 411-422. doi:10.1056/NEJMoa1001294

Lane, B. R., Smith, A. K., Larson, B. T., Gong, M. C., Campbell, S. C., Raghavan, D., . . . Stephenson, A. J. (2010). Chronic Kidney Disease After Nephroureterectomy for Upper Tract Urothelial Carcinoma and Implications for the Administration of Perioperative Chemotherapy. CANCER, 116(12), 2967-2973. doi:10.1002/cncr.25043

Shepard, D. R., & Dreicer, R. (2010). Zibotentan for the treatment of castrate-resistant prostate cancer. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 19(7), 899-908. doi:10.1517/13543784.2010.491822

Pili, R., Rosenthal, M. A., Mainwaring, P. N., Van Hazel, G., Srinivas, S., Dreicer, R., . . . Clingan, P. (2010). Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC. CLINICAL CANCER RESEARCH, 16(10), 2906-2914. doi:10.1158/1078-0432.CCR-09-3026

Rini, B. I., Garcia, J. A., Cooney, M. M., Elson, P., Tyler, A., Beatty, K., . . . Dreicer, R. (2010). Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 28(17), E284-E285. doi:10.1200/JCO.2009.27.1759

Dreicer, R., Garcia, J., Hussain, M., Rini, B., Vogelzang, N., Srinivas, S., . . . Raghavan, D. (2011). Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. INVESTIGATIONAL NEW DRUGS, 29(6), 1441-1448. doi:10.1007/s10637-010-9428-0

Barbastefano, J., Garcia, J. A., Elson, P., Wood, L. S., Lane, B. R., Dreicer, R., . . . Rini, B. I. (2010). Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU INTERNATIONAL, 106(9), 1266-1269. doi:10.1111/j.1464-410X.2010.09323.x

Chu, F. M., Picus, J., Fracasso, P. M., Dreicer, R., Lang, Z., & Foster, B. (2011). A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α_v integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. INVESTIGATIONAL NEW DRUGS, 29(4), 674-679. doi:10.1007/s10637-010-9388-4

Cooney, M. M., Bokar, J. A., Dreicer, R., Krishnamurthi, S. S., Savvides, P., Nock, C. J., . . . Dowlati, A. (2010). Phase I trial of daily pomalidomide in patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 28(15). doi:10.1200/jco.2010.28.15_suppl.e13077

Dreicer, R., Agus, D. B., MacVicar, G. R., Wang, J., MacLean, D., & Stadler, W. M. (2010). Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study. JOURNAL OF CLINICAL ONCOLOGY, 28(15). doi:10.1200/jco.2010.28.15_suppl.3084